Most doses of Lilly’s Mounjaro and Zepbound in limited availability, US FDA says

(Reuters) – The U.S. Food and Drug Administration website showed that most doses of Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarter of this year due to increased demand.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)